Africa and Europe Unite to Revolutionize RNA-Based Vaccines and Therapeutics Production In a groundbreaking collaboration, Africa’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences have signed a Memorandum of Understanding (MoU) to establish an innovative end-to-end RNA-based vaccine and…
Cardio Diagnostics Expands Reach with New Partnerships to Transform Heart Disease Prevention and Management Cardio Diagnostics Holdings a leading company in AI-driven Precision Cardiovascular Medicine, has announced the expansion of its innovative solutions with seven new provider partnerships. This strategic…
OS Therapies a clinical-stage biotechnology company focused on developing immunotherapies and targeted drug conjugates to treat cancer, has provided a comprehensive update to the market regarding its recent achievements and plans for the future. This announcement comes on the heels…
Cagent Vascular Announces the Launch of Serranator SL-PRO™ for Pedal and Tibial Disease Treatment Cagent Vascular a leader in the development of cutting-edge serration technology for vessel dilation in endovascular procedures, has unveiled its latest innovation: the Serranator SL-PRO™ PTA…
TriLink BioTechnologies® and Avantor® Partner to Expand Nucleic Acid Solutions in Europe TriLink BioTechnologies a Maravai® LifeSciences company and a global leader in providing cutting-edge life science reagents and services, has announced a strategic partnership with Avantor a renowned global…
D&D Pharmatech a clinical-stage biotechnology company dedicated to the development of disease-modifying therapeutics, has announced the successful completion of patient enrollment for DD01-DN-2, an ongoing Phase 2 clinical trial. This trial is designed to assess the efficacy and safety of…
Phase 3 Trial Pfizer has announced significant and positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER clinical trial. This trial assessed the efficacy of BRAFTOVI® in combination with cetuximab, marketed as ERBITUX®, and mFOLFOX6,…
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that it has secured a reimbursement agreement with NHS England, providing eligible sickle cell disease (SCD) patients access to its groundbreaking CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement represents a significant advancement in…
Owkin Achieves Milestone with First Patient Dosed in AI-Optimized Phase I Trial of OKN4395, a First-in-Class Triple Inhibitor for Solid Tumors On January 22, 2025, Owkin, the pioneering end-to-end AI biotech company transforming drug discovery, development, and diagnostics through agent-based…
Biologics Market 2024-2030: Global Industry Poised to Reach $732.4 Billion – Trends, Drivers, and Key Insights The global biologics market is experiencing unprecedented growth, with its value estimated at $421.1 billion in 2023 and projected to reach $732.4 billion by…
Medicare Drug Price Negotiation Program Sparks Concerns Over Pharmacy Viability and Patient Access The National Community Pharmacists Association (NCPA) has issued an urgent call for the immediate suspension of the Medicare Drug Price Negotiation Program (MDPNP), citing its potential to…
Revolutionizing Clinical Development: Science Exchange Launches Cutting-Edge Supplier Orchestration Solution In today’s rapidly evolving life sciences landscape, clinical development teams face mounting pressure to manage increasingly complex outsourcing arrangements. From functional service provider (FSP) models to full-service outsourcing (FSO), the…